This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Impact of ERBB mutations on clinical outcomes in afatinib- or erlotinib-treated patients with SqCC of the lung
Agnieszka Cseh, Glenwood D. Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Joo Min Young, Alessandro Morabito, Shirish M. Gadgeel, Neil Gibson, Nicole Krämer, Flavio Solca, Enriqueta Felip
Related Materials
Learn more about the science behind this poster in the videos, papers and other materials below.
FOR HEALTHCARE PROFESSIONALS ONLY.
In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.
In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.
